| 1 |
Mackenzie EF, Poulding JM, Harrison PR, et al. Human polyoma virus (HPV) - a significant pathogen in renal transplantation[J]. Proc Eur Dial Transplant Assoc, 1978，15：352-360.
|
| 2 |
Kean JM, Rao S, Wang M, et al. Seroepidemiology of human polyomaviruses[J]. PLoS Pathog, 2009，5(3)：e1000363.
|
| 3 |
Xue JL, Ma JZ, Louis TA, et al. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010[J]. J Am Soc Nephrol, 2001，12(12)：2753-2758.
|
| 4 |
中华医学会器官移植学分会. 器官移植受者BK病毒感染和BK病毒性肾病临床诊疗规范(2019版)[J]. 器官移植，2019, 10(3): 237-242.
|
| 5 |
Ramos E, Drachenberg CB, Wali R, et al. The decade of polyomavirus BK-associated nephropathy: state of affairs[J]. Transplantation, 2009，87(5)：621-630.
|
| 6 |
de Bruyn G, Limaye AP. BK virus-associated nephropathy in kidney transplant recipients[J]. Rev Med Virol, 2004，14(3)：193-205.
|
| 7 |
Huang G, Chen LZ, Qiu J, et al. Prospective study of polyomavirus BK replication and nephropathy in renal transplant recipients in China: a single center analysis of incidence, reduction in immunosuppression and clinical course[J]. Clin Transplant, 2010，24(5)：599-609.
|
| 8 |
Zakaria ZE, Elokely AM, Ghorab AA, et al. Screening for BK viremia/viruria and the impact of management of BK virus nephropathy in renal transplant recipients[J]. Exp Clin Transplant, 2019，17(Suppl 1)：83-91.
|
| 9 |
Mallon DH, Summers DM, Bradley JA, et al. Defining delayed graft function after renal transplantation: simplest is best[J]. Transplantation, 2013，96(10)：885-889.
|
| 10 |
Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients[J]. N Engl J Med, 2002，347(7)：488-496.
|
| 11 |
Nickeleit V, Singh HK, Randhawa P, et al. The Banff Working Group classification of definitive polyomavirus nephropathy: morphologic definitions and clinical correlations[J]. J Am Soc Nephrol, 2018，29(2)：680-693.
|
| 12 |
范宇，石炳毅，钱叶勇，等. 尿液与血液病毒载量在肾移植受者BK病毒性肾病诊断中的应用[J]. 中华器官移植杂志，2013，34(10)：595-599.
|
| 13 |
Stervbo U, Nienen M, Weist BJD, et al. BKV clearance time correlates with exhaustion state and T-cell receptor repertoire shape of BKV-specific T-cells in renal transplant patients[J]. Front Immunol, 2019，10：767.
|
| 14 |
Devresse A, Tinel C, Vermorel A, et al. No clinical benefit of rapid versus gradual tapering of immunosuppression to treat sustained BK virus viremia after kidney transplantation：a single-center experience[J]. Transpl Int, 2019，32(5)：481-492.
|
| 15 |
Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival[J]. N Engl J Med, 2013，369(13)：1215-1226.
|
| 16 |
Sood P, Senanayake S, Sujeet K, et al. Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study[J]. Transplantation, 2012，94(8)：814-821.
|
| 17 |
Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts[J]. Transplantation, 2013，95(3)：410-417.
|
| 18 |
Gatault P, Kamar N, Büchler M, et al. Reduction of extended-release tacrolimus dose in low-immunological-risk kidney transplant recipients increases risk of rejection and appearance of donor-specific antibodies: A randomized study[J]. Am J Transplant, 2017，17(5)：1370-1379.
|
| 19 |
Hardinger KL, Koch MJ, Bohl DJ, et al. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results[J]. Am J Transplant, 2010, 10(2)：407-415.
|
| 20 |
Santeusanio AD, Lukens BE, Eun J, et al. Antiviral treatment of BK virus viremia after kidney transplantation[J]. Am J Health Syst Pharm, 2017，74(24)：2037-2045.
|
| 21 |
Yuan X, Chen C, Zheng Y, et al. Conversion from mycophenolates to mizoribine is associated with lower BK virus load in kidney transplant recipients: A prospective study[J]. Transplant Proc, 2018，50(10)：3356-3360.
|
| 22 |
Shiraki K, Ishibashi M, Okuno T, et al. Effects of cyclosporine, azathioprine, mizoribine, and prednisolone on replication of human cytomegalovirus[J]. Transplant Proc, 1990，22(4)：1682-1685.
|